profit from every $100 of sales.
$0$100
Ingevity
$61.72-0.40% today
+22.1% in 1 year
1-year low $47.121-year high $77.87
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Ingevity sold, what it kept, and what it did with the cash.
Sales went from $1.67 billion in 2022 to $1.17 billion in 2025, with -$167 million of profit last year.
SalesProfit
Ingevity handed back 21% of the cash it generated last year.
Buybacks $56M
Free cash flow 2025$274M
Bought back its own shares$56M
Paid as dividends–
Cash vs. debt$78M vs. $1.2B
Ingevity vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Ingevity | No profit yet | ||
 PPG Industries | 17.2× · Fair price | ||
 LyondellBasell Industries | No profit yet | ||
 DuPont de Nemours | No profit yet | ||
 International Flavors & Fragrances | No profit yet |
AI analysis
An AI analyst reads Ingevity's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1,668 | 1,216 | 1,200 | 1,168 | |
| 570 | 445 | 465 | 462 | |
| 341 | 258 | 283 | 262 | |
| 440 | 346 | 64 | 41 | |
| 212 | -5 | -430 | -167 | |
| 5.50 | -0.15 | -11.85 | -4.61 | |
| 34.2% | 36.6% | 38.7% | 39.5% | |
| 20.4% | 21.2% | 23.5% | 22.4% | |
| 12.7% | -0.4% | -35.9% | -14.3% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 2,737 | 2,623 | 2,023 | 1,651 |
| Cash | 77 | 96 | 68 | 78 |
| Total debt | 1,531 | 1,535 | 1,449 | 1,243 |
| Total liabilities | 2,038 | 1,992 | 1,827 | 1,621 |
| 698 | 631 | 195 | 30 | |
| 39 | 37 | 36 | 36 | |
| 11.7% | 8.1% | -2.1% | -4.0% | |
| 30.3% | -0.9% | -220.4% | -562.6% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 313 | 205 | 129 | 331 | |
| 143 | 110 | 78 | 58 | |
| 171 | 95 | 51 | 274 | |
| Dividends paid | – | – | – | – |
| 145 | 92 | 0 | 56 | |
| 16 | 11 | 12 | 18 |
Valuation
- –
- 12.9×
- –
- 61.5×
- 1.8×
- 7.6×
- 78.5×
- 13.1%
- -8.0%
- 0.0%
Profitability
- 39.5%
- 22.4%
- -14.3%
- 3.3%
- 20.1%
- -4.8%
- -156.1%
- -7.7%
- 22.3%
- 2.4%
Growth
- −11.2%
- –
- +436.3%
- –
- −2.3%
Financial health
- 28.7×
- 32.00
- 75.4%
- 3.9×
- 1.42
- 0.92
- 0.73
How it ranks in Materials
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Top 8%of 990
Top 21%of 950
Bottom 9%of 929
Top 8%of 987
What analysts expect
- Average price target
- $76.67
- Range
- $65.00 – $83.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | 1.15 | 0.84 | +36.9% |
| Feb 25, 2026 | 0.58 | 0.67 | −12.8% |
| Nov 5, 2025 | 1.31 | 0.68 | +92.6% |
| Aug 4, 2025 | 1.39 | 1.02 | +36.3% |
| May 5, 2025 | 0.99 | 0.74 | +33.8% |
| Feb 18, 2025 | 0.95 | 0.29 | +227.6% |
| Oct 29, 2024 | 1.10 | 0.60 | +83.3% |
| Jul 31, 2024 | 1.01 | 1.05 | −3.8% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
37No pass
Benjamin Graham
9No pass
Philip Fisher
40No pass
Peter Lynch
2No pass
Joel Greenblatt
24No pass
Charlie Munger
34No pass
Terry Smith
24No pass
Questions about Ingevity
Is Ingevity a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Ingevity AI analysis
What does Ingevity do?
Ingevity Corporation manufactures and sells specialty chemicals and activated carbon materials in North America, the Asia Pacific, Europe, the Middle East, Africa, and South America. The company operates through two segments, Performance Materials and Performance Chemicals. It is in Chemicals - Specialty, based in North Charleston, SC, United States, with 1,400 employees.
Does Ingevity pay a dividend?
No. Ingevity does not pay a dividend at the moment; in 2025 it returned $56.3 million to shareholders by buying back its own shares.
Is Ingevity stock halal?
No. Ingevity does not pass our halal screen: its debt is 60% of its market value, at or above the 33% limit. How we check
How has Ingevity stock done over the past year?
Up 22.1% over the past twelve months, to $61.72. It traded between $47.12 and $77.87 and is 20.7% below its high.
Who are Ingevity's competitors?
The largest listed companies in the same industry are PPG Industries, LyondellBasell Industries, DuPont de Nemours and International Flavors & Fragrances. The peers table on this page compares their profit, growth and price with Ingevity's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.